NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS  «  1  2  3  4  5  » 
»02/05/2007 [Industry news]
Chinese pharma sales to exceed $46 billion by 2010

Bangalore, May 2, 2007: Market research firm Research and Markets, in its recently published report, China Pharmaceuticals and Healthcare Report Q4 2006, indicates that China is a burgeoning market....   more»


Covance »30/04/2007 [Company watch]
First Quarter 07 Results

copy of results...   more»


Charles River »08/05/2007 [Company watch]
Charles River announces 1st Quarter 2007 results

see full report...   more»


Charles River »24/04/2007 [Company watch]
Charles River Laboratories Appoints Cheri Walker, Ph.D. as Corporate Senior Vice President, Corporate Development

Charles River Laboratories International, Inc. (NYSE: CRL) announced today the appointment of Cheri Walker, Ph.D. to the role of Corporate Senior Vice President, Corporate Development, effective April 24, 2007. Dr. Walker will be responsible for the Company's global corporate development function, directing all aspects of our merger, acquisition and strategic joint venture activities. She will also participate as an integral member in the strategic planning process of the Company. Prior to joining Charles River, Dr. Walker was Vice President, Mergers and Acquisitions for QIAGEN Sciences where she oversaw the corporate development of QIAGEN's North American life sciences tools and molecular diagnostics businesses. Previously, Dr. Walker held senior corporate development and operational positions at Invitrogen where she successfully executed acquisition and licensing transactions. James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories noted, "We are delighted to have Cheri join the Charles River team. Her depth of experience in life science transactions adds greater strength to our management team." Dr. Walker commented, "I have followed the growth of Charles River for several years and am very excited to be joining a dynamic and expanding company. Corporate Development will play an integral role in this growth and I am looking forward to being part of the team." Dr. Walker holds a doctorate in Human and Molecular Genetics from Baylor College of Medicine and a bachelor's degree in Biology from Swarthmore College....   more»


»09/05/2007 [Finance]
Surge in buying on China's stock market

On Wednesday China's stock market traded more shares than all the other Asian stock markets put together....   more»


Novartis »23/04/2007 [Company watch]
Novartis with dynamic growth in the 2007 first quarter

Strong 2007 first quarter performance as Group net sales advance 18% (+15% in local currencies) to USD 9.8 billion on excellent performances from all divisions Group continuing operations operating income up 18%, net income up 17%...   more»


Eli Lilly & Co »04/05/2007 [Company watch]
Lilly Announces Senior Leadership Changes

Alex M. Azar II to join Lilly as senior vice president of corporate affairs and communications; Anne Nobles to assume role of chief compliance officer...   more»


Eli Lilly & Co »16/04/2007 [Company watch]
Lilly Reports Strong First-Quarter Results; Raises Full-Year Sales and EPS Guidance

Eli Lilly and Company (NYSE: LLY) today announced strong financial results for the first quarter of 2007 and raised its full-year sales and adjusted earnings per share guidance. First-Quarter Highlights * Sales increased 14 percent, to $4.226 billion....   more»


Wyeth »27/04/2007 [Company watch]
Wyeth Chief Financial Officer and Vice Chairman Kenneth J. Martin to Leave the Company

Madison, N.J., April 27, 2007 – Wyeth (NYSE: WYE) today announced that Chief Financial Officer (CFO) and Vice Chairman Kenneth J. Martin has announced plans to leave the Company at the end of June to pursue personal interests. Mr. Martin joined the Company in 1984 and has served as Chief Financial Officer since 2000. Wyeth plans to name a new CFO in advance of Mr. Martin’s departure. "Ken Martin has played key roles at Wyeth for many years and has been an important contributor to our success," says Robert Essner, Chairman and Chief Executive Officer, Wyeth...   more»


»11/05/2007 [Industry news]
Biotech industry's first five-year plan

The Council Office has announced its first five-year plan on biotech industry. The aim is to achieve a goal of 500 billion yuan (US$65 billion) in 2010, and 2 trillion yuan by 2020. In the five-year plan of the biotech industry, the focus area will be biomedicine, bio-agriculture, bio-energy and bio-manufacturing, according to the Shanghai Securities News.. To reach this high goals, the plan has four detailed objectives. The first is to initially form a supporting system to help developthe biotech industry. The second is to enhance innovation. The next objective is to optimize and upgrade the industry¡¯s structure. And finallyto expand the the biotech industry output....   more»


SinoBiomed »10/05/2007 [Company watch]
SinoBiomed facility gets GMP certification from SFDA

Chinese State Food and Drug Administration (SFDA) has recertified Shanghai Wanxing Bio-pharmaceuticals’ recombinant human interferon production plant as a Good Manufacturing Practice (GMP) facility. Shanghai Wanxing Bio-pharmaceuticals is a 82 percent owned subsidiary of China-based SinoBiomed. The 2,500 sq mt plant passed the local GMP re-certification inspection that the SFDA conducted from April 12 to 14, 2007 in Shanghai. The facility produces recombinant human interferon powder for injection. Recombinant human interferon is widely used for treating chronic hepatitis B, hepatitis C, a number of viral infections, and tumors. In meeting Chinese national drug GMP certification standards, the plant's heating ventilation air conditioning system achieved a grade of 100 in the SFDA’s air cleanliness classification, equivalent to a B grade in the US air cleanliness classification. The facility has one of China's largest production capacities and has produced some 12 million doses of recombinant human interferon since its initial five-year certification on December 12, 2001. The recertification authorizes production for another five-year term, ensuring quality control for the product as Shanghai Wanxing expands national and international distribution....   more»


China Biopharmaceuticals Holdings »10/05/2007 [Company watch]
China Biopharmaceuticals Holdings (CHBP) has named new officers and directors for its organization

The company has named Ms Zhang Jian as Chairwoman of the Board of Directors, Mr Shi Mingsheng as Chief Operating Officer and Mr Ding Weihua as member of the Board of Directors. The appointments come into effect from April 30, 2007. Ms Zhang Jian served as the General Manager of Suzhou Erye Pharmaceutical Company Limited (Erye) since 2003. Prior to being the General Manager for Erye, she served for more than five years as the deputy general manager of Suzhou Pharmaceutical Company. Ms Zhang has extensive background and experience in the pharmaceuticals industry having worked in various managerial positions and various aspects of the industry. She is known to be an expert in managing the growth of the company. In her new position, she will be overseeing the company's strategic growth and handle all responsibilities of the company’s operations. Mr Shi Mingsheng, named as the Chief Operating Officer of CHBP, previously served as the chairman of Suzhou Erye Pharmaceutical Company Limited since 2003. In association with Ms Zhang Jian, he built a profitable business, which currently has a joint venture with China Biopharmaceuticals. Mr Ding Weihua, elected to the Board of Directors of the company, is a veteran in the pharmaceuticals industry having worked in the field for more than 33 years. Mr Ding worked for nine years as deputy general manager and manager in sales and marketing at Erye. Prior to his positions in Erye, he worked for six years in business planning at Jiangsu Nantong Qinfen Pharmaceutical Company. “These new appointments not only add depth to our management team but demonstrate our commitment to enhancing our corporate governance. The experience that all three members bring from our most successful subsidiary to date, Eyre, will have an immediate positive impact on the management and performance of China Biopharmaceuticals,” said Mr Chris Peng Mao, Chief Executive Officer of China Biopharmaceuticals....   more»


GlaxoSmithKline »23/05/2007 [Company watch]
Glaxo to unveil major China drug research centre

LONDON, May 23 (Reuters) - GlaxoSmithKline Plc (GSK.L: Quote, Profile , Research) is set to unveil plans for major research and development centre in China, joining a growing number of pharmaceutical companies tapping into the country's skillbase in life sciences. Research head Moncef Slaoui told the annual meeting of Europe's biggest drugmaker on Wednesday that an announcement on the investment in a fully integrated research and development facility was imminent....   more»


»25/05/2007 [Industry news]
The first contract research service alliance (CROSA) in China

The first contract research service alliance (CROSA) in China has been formed between three leading local firms to provide a more exhaustive range of drug development services to pharma companies....   more»


»26/05/2007 [Independent reports]
China, India ahead of S'pore in race for pharmaceutical investments: PwC

SINGAPORE: Even as the Government injects large doses of resources to grow the life sciences industry, Singapore is apparently not the top choice for the majority of drug firms looking for places to pump their money into. According to a survey by PricewaterhouseCoopers (PwC), "China and India head the list of target countries for expansion, with Singapore and South Korea next in the sights of multinational corporations (MNCs)"....   more»


»22/05/2007 [Industry news]
PharmEng International Inc. ("PharmEng today that it has established a joint venture company

PharmEng International Inc. announced today that it has established a joint venture company in partnership with Beijing BRD Lixin PharmaTech Co. Ltd.("Lixin") of China to provide consulting and pharmaceutical development services in China. PharmEng will own 51% of the joint venture company, headquartered in Beijing, China and will operate under the name Beijing PharmEng BRD Lixin PharmaTech Consultation Co. Ltd....   more»


»22/05/2007 [Industry news]
Foreign investors are snapping up shares of companies in China's growing but under-regulated pharmaceutical industry, even as a string of deadly scandals has tainted the sector.

Comment:: Its not just foreign investors! China's Gvmt is threatening to bring in measures to contain the trading in shares by the ordinary chinese people, causing ridiculous inflated values to some of the listed companies. It's creating a scenario similar to the dotcom era experienced here in the west....   more»


»21/05/2007 [Industry news]
Protagen and ZAP partner with Kangdi Antibody Biotech and Bejing Proteome Research Centre to develop

Protagen announced its partnership with the Centre for Applied Proteomics (ZAP), Dortmund, Schunde Kangdi Antibody Biotech, Foshan, China and the Beijing Proteome Research Centre (Beijing PRC) today at the interna?tional symposium on High Performance Proteomics in Dortmund....   more»


»03/06/2007 [Industry news]
Now China targets traditional medicine factory

China has raided a filthy underground fake medicine factory, Chinese media reported on Thursday, as the country faces a series of food and medicine safety scandals at home and abroad....   more»


Simcere Pharmaceutical Group »03/06/2007 [Industry news]
Simcere Pharmaceutical Group is looking to build its future on research

Flush with cash from its US IPO, Simcere Pharmaceutical Group is looking to build its future on research. Late last month, Simcere weighed in with the largest IPO on the New York Stock Exchange for an Asian pharmaceutical company, raising 261 mln usd. Now it plans to put some of that money to work. 'We need to consider both the long-term and the short-term,' said Jinsheng Ren, chairman and CEO. 'Pharmaceutical technology can really set companies apart in China and that is why we say R & D is our focus.' "THIS HIGHLY RESPECTED COMPANY COULD BE A GOOD PARTNER FOR HLS"...   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.